ZBTB38 and prostate neoplasm: ZBTB38 mRNA expression, in combination with other genetic alterations (i.e., SPOP/SPOPL), might thus be useful to identify localised prostate tumours that will exhibit more aggressive behaviour and target metastasis with doxorubicin-based therapies.